43
Participants
Start Date
April 30, 2011
Primary Completion Date
February 28, 2015
Study Completion Date
April 19, 2016
Ofatumumab
"1000mg vials (50ml @ 20mg/ml), or 100mg vials (5ml @20mg/ml), to be given as an Intravenous (IV) infusion.~Ofatumumab will be infused intravenously on day 1 (300 mg), day 8 (1000 mg) and day 15 (1000mg) in the first cycle, followed by infusions every 3 weeks of 1000 mg on the first day of each cycle for a total of 6 cycles. Maintenance treatment will start 4 weeks after day 1 of cycle 6 in week 20 and consists of six infusions of ofatumumab every 8 weeks"
Queen Elizabeth Hospital Birmingham, Birmingham
Royal Bournemouth Hospital, Bournemouth
Addenbrooke's Hospital, Cambridge
St James University Hospital, Leeds
Royal Liverpool University Hospital, Liverpool
St Bartholomew's Hospital, London
Kings College Hospital, London
Christie Hospital, Manchester
Churchill Hospital, Oxford
Collaborators (2)
GlaxoSmithKline
INDUSTRY
Cancer Research UK
OTHER
Oxford University Hospitals NHS Trust
OTHER
NCRI CLL Subgroup
UNKNOWN
University of Oxford
OTHER